Alterity Therapeutics Limited, a development stage enterprise, has filed its corporate governance statement for the financial year ended June 30, 2024, with the Securities and Exchange Commission (SEC) as part of its Form 6-K filing for September 2024. The statement, which is current as of September 26, 2024, details the company's compliance with the ASX Corporate Governance Council's recommendations. It includes disclosures on board composition, diversity policy, risk management, and other key governance aspects. The company has chosen to provide this information on its website, with specific URLs given for each section of the corporate governance statement. Alterity Therapeutics has also confirmed that it does not have a nomination committee, instead disclosing the processes it employs to address board succession issues and ensure an appropriate balance of skills and diversity. The company has followed the majority of the recommendations, with detailed disclosures provided for each. The full corporate governance statement is available on Alterity Therapeutics' website, offering transparency to investors and stakeholders regarding the company's governance practices and policies.

Alterity Therapeutics Limited, a development stage enterprise, has filed its corporate governance statement for the financial year ended June 30, 2024, with the Securities and Exchange Commission (SEC) as part of its Form 6-K filing for September 2024. The statement, which is current as of September 26, 2024, details the company's compliance with the ASX Corporate Governance Council's recommendations. It includes disclosures on board composition, diversity policy, risk management, and other key governance aspects. The company has chosen to provide this information on its website, with specific URLs given for each section of the corporate governance statement. Alterity Therapeutics has also confirmed that it does not have a nomination committee, instead disclosing the processes it employs to address board succession issues and ensure an appropriate balance of skills and diversity. The company has followed the majority of the recommendations, with detailed disclosures provided for each. The full corporate governance statement is available on Alterity Therapeutics' website, offering transparency to investors and stakeholders regarding the company's governance practices and policies.